Literature DB >> 7910668

Operative sepsis in neurosurgery: a method of classifying surgical cases.

P K Narotam1, J R van Dellen, M D du Trevou, E Gouws.   

Abstract

Neurosurgical operations have traditionally been classified along the lines of general surgical procedures. A prospective study, during an 18-month period, was undertaken in 2249 patients undergoing neurosurgical procedures to establish and evaluate a method of classifying surgical cases by the use of specific neurosurgical criteria. Patients were placed in one of five categories according to the level and type of contamination at the time of surgery. Infection included all abnormal wounds and was documented as deep when infection occurred beneath the galea (subgaleal pus, osteitis, abscess/empyema, ventriculomeningitis) and as superficial if only the scalp (including wound erythema) was involved. A statistically significant difference in the sepsis rate was found in the different categories (P < 0.0001). Of the 342 "dirty cases," 9.1% of patients developed further wound sepsis. Concomitant cerebrospinal fluid fistulae (44%), second operations (11.8%), and patients with penetrating injuries (9.2%) were the major factors implicated in sepsis in the "contaminated" category (9.7%). In the "clean contaminated" category, a sepsis rate of 6.8% was found. Prolonged surgery (longer than 4 hours) was also implicated in higher infection rates (13.4%). This study strongly supports the separation of patients who have foreign materials implanted (sepsis rate = 6.0%) from "clean" patients, essentially cases categorized as having no known risk factors that may affect sepsis, in whom a sepsis rate of 0.8% was found (P < 0.001). Importantly, surgery for the repair of so-called "clean" neural tube defects in neonates requires separate consideration. An infection rate of 14.8% existed in this subgroup. A uniform system of reporting wound abnormalities is also proposed.

Entities:  

Mesh:

Year:  1994        PMID: 7910668     DOI: 10.1227/00006123-199403000-00004

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  7 in total

1.  Unnecessary surgical treatment of fungal kerions in children.

Authors:  K L Gibbon; P Goldsmith; J A Salisbury; A P Bewley
Journal:  BMJ       Date:  2000-03-11

Review 2.  Prophylactic antibiotics in pediatric neurological surgery.

Authors:  Friederike Knerlich-Lukoschus; Martina Messing-Jünger
Journal:  Childs Nerv Syst       Date:  2018-06-16       Impact factor: 1.475

3.  Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens.

Authors:  Wei-Wei Lin; Wei Wu; Zheng Jiao; Rong-Fang Lin; Chang-Zhen Jiang; Pin-Fang Huang; Yi-Wei Liu; Chang-Lian Wang
Journal:  Eur J Clin Pharmacol       Date:  2015-10-01       Impact factor: 2.953

4.  Surgical site infections following craniotomy focusing on possible post-operative acquisition of infection: prospective cohort study.

Authors:  O Sneh-Arbib; A Shiferstein; N Dagan; S Fein; L Telem; E Muchtar; N Eliakim-Raz; B Rubinovitch; G Rubin; Z H Rappaport; M Paul
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-06-11       Impact factor: 3.267

5.  Neuron-Specific Enolase Is Correlated to Compromised Cerebral Metabolism in Patients Suffering from Acute Bacterial Meningitis; An Observational Cohort Study.

Authors:  Jiri Bartek; Eric Peter Thelin; Per Hamid Ghatan; Martin Glimaker; Bo-Michael Bellander
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

6.  Prospective Multicenter Surveillance Study of Surgical Site Infection after Intracranial Procedures in Korea : A Preliminary Study.

Authors:  Tae Seok Jeong; Gi Taek Yee
Journal:  J Korean Neurosurg Soc       Date:  2018-08-31

7.  Microdialysis Monitoring of CSF Parameters in Severe Traumatic Brain Injury Patients: A Novel Approach.

Authors:  Eric P Thelin; David W Nelson; Per Hamid Ghatan; Bo-Michael Bellander
Journal:  Front Neurol       Date:  2014-09-02       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.